116 related articles for article (PubMed ID: 21740293)
1. Development of c-MET pathway inhibitors.
Liu X; Newton RC; Scherle PA
Expert Opin Investig Drugs; 2011 Sep; 20(9):1225-41. PubMed ID: 21740293
[TBL] [Abstract][Full Text] [Related]
2. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
Liu X; Newton RC; Scherle PA
Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
[TBL] [Abstract][Full Text] [Related]
3. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
4. Targeting angiogenesis in renal cell carcinoma.
Posadas EM; Limvorasak S; Sharma S; Figlin RA
Expert Opin Pharmacother; 2013 Nov; 14(16):2221-36. PubMed ID: 23984807
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
6. Targeting the MET pathway for potential treatment of NSCLC.
Li A; Gao HF; Wu YL
Expert Opin Ther Targets; 2015 May; 19(5):663-74. PubMed ID: 25532429
[TBL] [Abstract][Full Text] [Related]
7. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H; Rost S; Yauch RL
J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
[TBL] [Abstract][Full Text] [Related]
8. [A simple view on lung cancer biology: the MET pathway].
Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
[TBL] [Abstract][Full Text] [Related]
9. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
10. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
11. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.
Hung CM; Kuo DH; Chou CH; Su YC; Ho CT; Way TD
J Agric Food Chem; 2011 Sep; 59(17):9683-90. PubMed ID: 21806057
[TBL] [Abstract][Full Text] [Related]
12. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
Feng Y; Thiagarajan PS; Ma PC
J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
14. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
15. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
17. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
19. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
20. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors.
Bagai R; Fan W; Ma PC
IDrugs; 2010 Jun; 13(6):404-14. PubMed ID: 20506063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
